PANICHELLA, GIORGIA
PANICHELLA, GIORGIA
Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis
2022-01-01 Morfino, P.; Aimo, A.; Panichella, G.; Rapezzi, C.; Emdin, M.
Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers
2022-01-01 Chianca, M.; Panichella, G.; Fabiani, I.; Giannoni, A.; L'Abbate, S.; Aimo, A.; Del Franco, A.; Vergaro, G.; Grigoratos, C.; Castiglione, V.; Cipolla, C. M.; Fedele, A.; Passino, C.; Emdin, M.; Cardinale, D. M.
Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis
2022-01-01 Aimo, A.; Iborra-Egea, O.; Martini, N.; Galvez-Monton, C.; Burchielli, S.; Panichella, G.; Passino, C.; Emdin, M.; Bayes-Genis, A.
Indications of beta-adrenoceptor blockers in Takotsubo syndrome and theoretical reasons to prefer agents with vasodilating activity
2021-01-01 Aimo, A.; Pelliccia, F.; Panichella, G.; Vergaro, G.; Barison, A.; Passino, C.; Emdin, M.; Camici, P. G.
Pirfenidone as a novel cardiac protective treatment
2021-01-01 Aimo, A.; Spitaleri, G.; Panichella, G.; Lupon, J.; Emdin, M.; Bayes-Genis, A.
Sex-related differences in ventricular remodeling after myocardial infarction
2021-01-01 Aimo, A.; Panichella, G.; Barison, A.; Maffei, S.; Cameli, M.; Coiro, S.; D'Ascenzi, F.; Di Mario, C.; Liga, R.; Marcucci, R.; Morrone, D.; Olivotto, I.; Tritto, I.; Emdin, M.
Subclinical cardiac damage in cancer patients before chemotherapy
2021-01-01 Fabiani, I.; Panichella, G.; Aimo, A.; Grigoratos, C.; Vergaro, G.; Pugliese, N. R.; Taddei, S.; Cardinale, D. M.; Passino, C.; Emdin, M.; Giannoni, A.
The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction
2021-01-01 Aimo, A.; Castiglione, V.; Vergaro, G.; Panichella, G.; Senni, M.; Lombardi, C. M.; Emdin, M.
The Potential Anti-remodeling Effect of Paroxetine After Myocardial Infarction May Be Blunted by Beta-Blockers
2022-01-01 Iborra-Egea, O.; Aimo, A.; Martini, N.; Galvez-Monton, C.; Burchielli, S.; Panichella, G.; Passino, C.; Emdin, M.; Bayes-Genis, A.
Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis
2022-01-01 Tomasoni, D.; Aimo, A.; Merlo, M.; Nardi, M.; Adamo, M.; Bellicini, M. G.; Cani, D.; Franzini, M.; Khalil, A.; Pancaldi, E.; Panichella, G.; Porcari, A.; Rossi, M.; Vergaro, G.; Lombardi, C. M.; Sinagra, G.; Rapezzi, C.; Emdin, M.; Metra, M.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis | 1-gen-2022 | Morfino, P.; Aimo, A.; Panichella, G.; Rapezzi, C.; Emdin, M. | |
| Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers | 1-gen-2022 | Chianca, M.; Panichella, G.; Fabiani, I.; Giannoni, A.; L'Abbate, S.; Aimo, A.; Del Franco, A.; Vergaro, G.; Grigoratos, C.; Castiglione, V.; Cipolla, C. M.; Fedele, A.; Passino, C.; Emdin, M.; Cardinale, D. M. | |
| Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis | 1-gen-2022 | Aimo, A.; Iborra-Egea, O.; Martini, N.; Galvez-Monton, C.; Burchielli, S.; Panichella, G.; Passino, C.; Emdin, M.; Bayes-Genis, A. | |
| Indications of beta-adrenoceptor blockers in Takotsubo syndrome and theoretical reasons to prefer agents with vasodilating activity | 1-gen-2021 | Aimo, A.; Pelliccia, F.; Panichella, G.; Vergaro, G.; Barison, A.; Passino, C.; Emdin, M.; Camici, P. G. | |
| Pirfenidone as a novel cardiac protective treatment | 1-gen-2021 | Aimo, A.; Spitaleri, G.; Panichella, G.; Lupon, J.; Emdin, M.; Bayes-Genis, A. | |
| Sex-related differences in ventricular remodeling after myocardial infarction | 1-gen-2021 | Aimo, A.; Panichella, G.; Barison, A.; Maffei, S.; Cameli, M.; Coiro, S.; D'Ascenzi, F.; Di Mario, C.; Liga, R.; Marcucci, R.; Morrone, D.; Olivotto, I.; Tritto, I.; Emdin, M. | |
| Subclinical cardiac damage in cancer patients before chemotherapy | 1-gen-2021 | Fabiani, I.; Panichella, G.; Aimo, A.; Grigoratos, C.; Vergaro, G.; Pugliese, N. R.; Taddei, S.; Cardinale, D. M.; Passino, C.; Emdin, M.; Giannoni, A. | |
| The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction | 1-gen-2021 | Aimo, A.; Castiglione, V.; Vergaro, G.; Panichella, G.; Senni, M.; Lombardi, C. M.; Emdin, M. | |
| The Potential Anti-remodeling Effect of Paroxetine After Myocardial Infarction May Be Blunted by Beta-Blockers | 1-gen-2022 | Iborra-Egea, O.; Aimo, A.; Martini, N.; Galvez-Monton, C.; Burchielli, S.; Panichella, G.; Passino, C.; Emdin, M.; Bayes-Genis, A. | |
| Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis | 1-gen-2022 | Tomasoni, D.; Aimo, A.; Merlo, M.; Nardi, M.; Adamo, M.; Bellicini, M. G.; Cani, D.; Franzini, M.; Khalil, A.; Pancaldi, E.; Panichella, G.; Porcari, A.; Rossi, M.; Vergaro, G.; Lombardi, C. M.; Sinagra, G.; Rapezzi, C.; Emdin, M.; Metra, M. |